Project Grant R15NS143081
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$473K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Similar Awards
This Project Grant award of $455,371 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development and validation of a novel microchip-based platform for the discovery and characterization of migraine therapies. The key products and services to be delivered under this award include: Quantifying comprehensive neurovascular and behavioral responses to established migraine triggers and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,375.00 to support research on the role of the GPR37L1 receptor in chronic migraine. The funding will enable a research team at Florida Atlantic University, with a sub-award to the University of Florida, to conduct a comprehensive investigation into the involvement of GPR37L1 signaling in the neuropathology of...
This $444,125 Project Grant, awarded on July 18, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of progesterone receptors in regulating the transition from episodic to chronic migraine. The key objectives are to: 1) Use mouse models to assess how modulating progesterone receptor signaling affects migraine...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $475,475 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on the pathophysiology of morning migraine. The key objectives of this 2-year award are to: 1) Define the quantitative and qualitative profiles of complement and purinergic receptors and regulators...
This Project Grant award of $650,079 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop selective probes targeting the α9 nicotinic acetylcholine receptor (α9*-nAChR) for treating chronic inflammatory and neuropathic pain. The key objectives are to: 1) Develop small-molecule agonists and antagonists of α9*-nAChR through structure-activity...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $603,406 to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medicines and reducing opioid-related side effects. The project aims to optimize potency, selectivity, and drug-like properties of GPR139...
This Project Grant award of $547,846 from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders will support research to optimize and characterize small molecule GPR17 antagonists for potential treatment of multiple sclerosis (MS). The key objectives are to: 1) synthesize at least 100 novel analogs of the lead compound SN-191 through structural modifications, 2) evaluate the synthesized...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", provides $620,278 to the University of Maryland, Baltimore to investigate the molecular basis for using sphingosine-1-phosphate receptor 1 (S1PR1) antagonists to treat the comorbid conditions of migraine and temporomandibular disorders (TMDs). The research aims to establish...
This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...